Tag: Secukinumab
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration's approval of Cosentyx (secukinumab) for treating adults with moderate to ... Read More
EC approves label update for Novartis psoriatic arthritis drug Cosentyx
The European Commission (EC) has approved a label update for Novartis psoriatic arthritis drug Cosentyx (secukinumab) to include dosing flexibility for treating the condition. Cosentyx ... Read More